CSF2 and metastatic melanoma: In another clinical study on metastatic melanoma patients, treatment with T-VEC showed a better durable response rate (continuous complete response or partial response lasting ≥ 6 months) over subcutaneous GM-CSF (16.3% vs. 2.1%; p < 0.001).